Cara Therapeutics, Inc. (CARA)
| Market Cap | 503.22M |
| Revenue (ttm) | 25.88M |
| Net Income (ttm) | -92.89M |
| Shares Out | 53.59M |
| EPS (ttm) | -1.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 602,769 |
| Open | 9.26 |
| Previous Close | 9.12 |
| Day's Range | 9.04 - 9.45 |
| 52-Week Range | 7.40 - 18.93 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 25.50 (+171.6%) |
| Earnings Date | Aug 8, 2022 |
About CARA
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialy... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for CARA stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 171.57% from the latest price.
News
Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of 7.14% and 69.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics Reports First Quarter 2022 Financial Results
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation
Cara Therapeutics to Present at May Investor Conferences
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pat...
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022
STAMFORD, Conn., April 29, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of p...
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Europe...
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of p...
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Select...
Poster highlights reduction in itch intensity with difelikefalin treatment correlated with reductions in inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemod...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermati...
Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual Meeting Data presented in late-breaking session at the 2022 American Academy of Dermatology (AAD) Annual ...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 Americ...
Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients
Cara Therapeutics (CARA) Reports Q4 Loss, Lags Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -26% and 77.32%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
ST. GALLEN, Switzerland & STAMFORD, Conn.--(BUSINESS WIRE)--Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the Europe...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pa...
Cara Therapeutics To Host Virtual R&D On March 11
Joana Goncalves, MD, chief medical officer of Cara Therapeutics Brian Kim, MD, MTR,
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
Presentation to highlight oral difelikefalin Phase 3 pruritus programs Presentation to highlight oral difelikefalin Phase 3 pruritus programs
Earnings Preview: Cara Therapeutics (CARA) Q4 Earnings Expected to Decline
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of pa...
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
KORSUVA receives TDAPA reimbursement beginning April 2022
Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical enti...
Cara Therapeutics to Present at Upcoming Investor Conferences
STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of 94.44% and 28.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics Reports Third Quarter 2021 Financial Results
– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administratio...
Cara Therapeutics Announces CEO Transition
Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA™ (difelikefalin)...
3 Explosive Biotech Stocks -- Could They Shoot Even Higher?
These biotech stocks have recently been responsible for a slew of rocketship emojis.
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allevia...